ANI Pharma Inc is a specialty pharmaceutical company focused on developing and commercializing a range of high-quality generic and branded prescription products, primarily in the fields of pain management, endocrinology, and complex formulations
The company aims to address the unique needs of patients by leveraging its expertise in drug formulation and development, while also striving to enhance patient access to its medications. ANI Pharma places a strong emphasis on innovation and quality, utilizing advanced technology to create differentiated products that target specific therapeutic areas.
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial sales growth and an optimistic FY 2024 outlook.
BALA CYNWYD, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close in Q3 2024.
